ABioC Technology -- A New Method for Treating Difficult to Treat Orthopedic Diseases

Derived from autologous cells and growth factors, it eliminates the risks of immune rejection and disease transmission. Utilizing tissue engineering and regenerative medicine techniques, it achieves the regenerative repair of damaged tissues. With a minimally invasive treatment approach, it avoids secondary surgery, accelerates tissue repair, and saves medical costs. By integrating existing medical technologies, it serves as the icing on the cake.  

Introduction to ABioC Tissue Regeneration Technology (ABC)

With the rapid development of modern medicine, tissue regeneration has gradually become a reality. In 2008, the International Olympic Committee established a panel of sports medicine experts to issue a "Consensus Statement", which believed that tissue regeneration treatment technology based on cytokines and cells would bring good news to patients and was the trend of sports medicine development, and it was first clinically applied in sports system injuries.

Human tissue is composed of tissue cells, extracellular matrix secreted by cells, cell growth factors, water, and other tissue elements. Traditional treatment techniques involve preventing disease progression through medication and surgically removing necrotic tissue. Regenerating diseased and damaged tissues to restore structure and function has been a long-sought aspiration. With the rapid development of biomedicine, cell medicine, tissue engineering, and regenerative medicine technologies, tissue regeneration has gradually become a reality, and it has been clinically applied primarily in sports system injuries. ABioC tissue regeneration technology, as a product of modern medical development, brings new hope to patients with intractable orthopedic diseases.

Autologous Bioactive Concentrates (ABioC): a general term for bioactive substances such as autologous cells, growth factors, anti-inflammatory factors, and fibrin. ABioC primarily includes autologous factors derived from peripheral blood, bone marrow cells derived from bone marrow or tissue cells, hyaline cartilage cells, meniscus cartilage cells, tendon cells, and adipocytes. ABioCTM tissue regeneration technology is a tissue engineering and regenerative medicine technology based on autologous cells and growth factors. ABioCTM technology is divided into one type and three types of medical technologies according to different ways of achieving tissue regeneration:

In-situ tissue regeneration technology (a type of medical technology): an in vivo tissue engineering technology based on autologous bioactive concentrates and conducted according to the principles of regenerative medicine, which directly creates a suitable local regenerative microenvironment at the defect site in the body, provides tissue regeneration elements such as cells, growth factors, and biomaterials, and promotes the in-situ regeneration of the defective tissue.

Tissue Engineering Tissue Transplantation Technology (Class III Medical Technology): A cell transplantation treatment technology or tissue engineering tissue transplantation technology based on autologous cell expansion and guided by regenerative medicine principles, where tissue cells are cultured and expanded in GMP conditions for local cell transplantation treatment, or expanded cells are seeded onto biological materials (composites) for tissue engineering tissue transplantation at the defect site in the body.